A detailed history of Schonfeld Strategic Advisors LLC transactions in Immunic, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 53,000 shares of IMUX stock, worth $58,830. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,000
Previous 129,700 59.14%
Holding current value
$58,830
Previous $194,000 64.43%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.14 - $1.53 $87,437 - $117,351
-76,700 Reduced 59.14%
53,000 $69,000
Q4 2023

Feb 14, 2024

SELL
$0.97 - $1.6 $105,730 - $174,400
-109,000 Reduced 45.66%
129,700 $194,000
Q3 2023

Nov 14, 2023

BUY
$1.35 - $2.87 $86,130 - $183,106
63,800 Added 36.48%
238,700 $350,000
Q2 2023

Aug 14, 2023

BUY
$1.33 - $2.51 $55,727 - $105,168
41,900 Added 31.5%
174,900 $438,000
Q1 2023

May 15, 2023

BUY
$1.35 - $2.87 $179,550 - $381,710
133,000 New
133,000 $198,000
Q3 2022

Nov 14, 2022

BUY
$3.21 - $5.49 $8,667 - $14,823
2,700 Added 2.65%
104,400 $330,000
Q2 2022

Aug 15, 2022

BUY
$3.13 - $12.25 $64,791 - $253,575
20,700 Added 25.56%
101,700 $353,000
Q1 2022

May 16, 2022

BUY
$9.54 - $14.26 $235,637 - $352,222
24,700 Added 43.87%
81,000 $916,000
Q4 2021

Feb 14, 2022

BUY
$7.34 - $10.25 $13,946 - $19,475
1,900 Added 3.49%
56,300 $539,000
Q3 2021

Nov 16, 2021

BUY
$8.05 - $13.29 $28,175 - $46,515
3,500 Added 6.88%
54,400 $482,000
Q2 2021

Aug 16, 2021

BUY
$11.76 - $16.85 $103,488 - $148,280
8,800 Added 20.9%
50,900 $624,000
Q1 2021

May 17, 2021

BUY
$14.21 - $25.3 $35,525 - $63,250
2,500 Added 6.31%
42,100 $671,000
Q4 2020

Feb 16, 2021

SELL
$14.8 - $20.37 $766,640 - $1.06 Million
-51,800 Reduced 56.67%
39,600 $605,000
Q3 2020

Nov 16, 2020

BUY
$11.74 - $22.0 $651,570 - $1.22 Million
55,500 Added 154.6%
91,400 $2,000
Q2 2020

Aug 14, 2020

BUY
$5.67 - $15.86 $203,553 - $569,374
35,900 New
35,900 $435,000

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $33.9M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.